AR042480A1 - Derivados de la quinazolina para el trtamiento del crecimiento celular anormal - Google Patents
Derivados de la quinazolina para el trtamiento del crecimiento celular anormalInfo
- Publication number
- AR042480A1 AR042480A1 ARP030104645A ARP030104645A AR042480A1 AR 042480 A1 AR042480 A1 AR 042480A1 AR P030104645 A ARP030104645 A AR P030104645A AR P030104645 A ARP030104645 A AR P030104645A AR 042480 A1 AR042480 A1 AR 042480A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- formula
- quinazoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a procedimientos de tratamiento del crecimiento celular anormal en mamíferos mediante la administración de los compuestos de fórmula (1), y a composiciones farmacéuticas para tratar dichos trastornos que contienen los compuestos de fórmula (1), y a procedimientos de preparación. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal, solvato o profármaco farmacéuticamente aceptable del mismo, en la que: R1 se selecciona del grupo constituido por H, y alquilo C1-6; R2 se selecciona del grupo constituido por H, grupos alquilo C1-10, alcoxi C1-6 e hidroxialquilo C1-6; R3 se selecciona del grupo constituido por H, alquilo C1-6, hidroxialquilo C1-6 y C(O)OR4, estando seleccionado R4 del grupo constituido por H y alquilo C1-6; R5 se selecciona del grupo constituido por -C(O)OH y -(CR6R7)m-NR1R8, en la que m es un número entero de 0 a 3; cada R6 y R7 está independientemente seleccionado del grupo constituido por H y alquilo C1-6, y en la que R8 se selecciona del grupo constituido por alquilo C1-6 y -C(O)-(CR6R7)m-O(alquilo C1-6); y en la que el compuesto de fórmula (1) está opcionalmente sustituido además con un hidroxi o un sustituyente ácido O-glucurónico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43448602P | 2002-12-18 | 2002-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042480A1 true AR042480A1 (es) | 2005-06-22 |
Family
ID=32595280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104645A AR042480A1 (es) | 2002-12-18 | 2003-12-16 | Derivados de la quinazolina para el trtamiento del crecimiento celular anormal |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040254204A1 (es) |
| EP (1) | EP1575592A1 (es) |
| JP (1) | JP2006513179A (es) |
| KR (1) | KR20050085749A (es) |
| CN (1) | CN1729001A (es) |
| AR (1) | AR042480A1 (es) |
| AU (1) | AU2003303045A1 (es) |
| BR (1) | BR0317433A (es) |
| CA (1) | CA2510323A1 (es) |
| GT (1) | GT200300286A (es) |
| MX (1) | MXPA05006335A (es) |
| NL (1) | NL1025044C2 (es) |
| NO (1) | NO20053483L (es) |
| PA (1) | PA8592801A1 (es) |
| PE (1) | PE20040905A1 (es) |
| PL (1) | PL377686A1 (es) |
| RU (1) | RU2005119172A (es) |
| TW (1) | TW200424190A (es) |
| WO (1) | WO2004054585A1 (es) |
| ZA (1) | ZA200504147B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| KR20060037447A (ko) * | 2003-08-18 | 2006-05-03 | 화이자 프로덕츠 인크. | ｅｒｂＢ２ 항암제에 대한 투약 스케쥴 |
| ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| US8236823B2 (en) | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| KR20250123237A (ko) | 2009-01-16 | 2025-08-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711783A1 (en) * | 1994-11-08 | 1996-05-15 | Glaxo, S.A. | Antifungal Sordarin derivatives |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| KR20020032612A (ko) * | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 유도체 및 그의 의약으로서의 용도 |
| JP4810043B2 (ja) * | 2000-01-18 | 2011-11-09 | ネリアス・ファーマシュティカルズ・インコーポレーテッド | 細胞分裂阻害剤及びその製造方法 |
| JP4044839B2 (ja) * | 2000-06-22 | 2008-02-06 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するための置換２環式誘導体 |
| ES2295409T3 (es) * | 2001-11-30 | 2008-04-16 | Osi Pharmaceuticals, Inc. | Procedimiento para la preparacion de derivados biciclicos sustituidos para el tratamiento de crecimiento anormal de celulas. |
| HRP20040529A2 (en) * | 2001-12-12 | 2004-10-31 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth |
| WO2003050108A1 (en) * | 2001-12-12 | 2003-06-19 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
-
2003
- 2003-12-08 RU RU2005119172/04A patent/RU2005119172A/ru not_active Application Discontinuation
- 2003-12-08 AU AU2003303045A patent/AU2003303045A1/en not_active Abandoned
- 2003-12-08 CN CNA2003801069555A patent/CN1729001A/zh active Pending
- 2003-12-08 WO PCT/IB2003/005826 patent/WO2004054585A1/en not_active Ceased
- 2003-12-08 BR BR0317433-6A patent/BR0317433A/pt not_active IP Right Cessation
- 2003-12-08 KR KR1020057011285A patent/KR20050085749A/ko not_active Ceased
- 2003-12-08 CA CA002510323A patent/CA2510323A1/en not_active Abandoned
- 2003-12-08 MX MXPA05006335A patent/MXPA05006335A/es unknown
- 2003-12-08 PL PL377686A patent/PL377686A1/pl not_active Application Discontinuation
- 2003-12-08 JP JP2004560067A patent/JP2006513179A/ja active Pending
- 2003-12-08 EP EP03813249A patent/EP1575592A1/en not_active Withdrawn
- 2003-12-10 PE PE2003001246A patent/PE20040905A1/es not_active Application Discontinuation
- 2003-12-16 GT GT200300286A patent/GT200300286A/es unknown
- 2003-12-16 US US10/737,691 patent/US20040254204A1/en not_active Abandoned
- 2003-12-16 AR ARP030104645A patent/AR042480A1/es unknown
- 2003-12-17 TW TW092135744A patent/TW200424190A/zh unknown
- 2003-12-17 PA PA20038592801A patent/PA8592801A1/es unknown
- 2003-12-17 NL NL1025044A patent/NL1025044C2/nl not_active IP Right Cessation
-
2005
- 2005-05-23 ZA ZA200504147A patent/ZA200504147B/en unknown
- 2005-07-18 NO NO20053483A patent/NO20053483L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040905A1 (es) | 2005-01-18 |
| CN1729001A (zh) | 2006-02-01 |
| EP1575592A1 (en) | 2005-09-21 |
| RU2005119172A (ru) | 2006-01-20 |
| JP2006513179A (ja) | 2006-04-20 |
| CA2510323A1 (en) | 2004-07-01 |
| ZA200504147B (en) | 2006-07-26 |
| KR20050085749A (ko) | 2005-08-29 |
| TW200424190A (en) | 2004-11-16 |
| NO20053483D0 (no) | 2005-07-18 |
| BR0317433A (pt) | 2005-11-16 |
| NL1025044A1 (nl) | 2004-06-21 |
| NL1025044C2 (nl) | 2005-02-15 |
| PL377686A1 (pl) | 2006-02-06 |
| MXPA05006335A (es) | 2005-08-26 |
| WO2004054585A1 (en) | 2004-07-01 |
| NO20053483L (no) | 2005-09-19 |
| AU2003303045A1 (en) | 2004-07-09 |
| GT200300286A (es) | 2004-08-13 |
| PA8592801A1 (es) | 2004-07-26 |
| US20040254204A1 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042480A1 (es) | Derivados de la quinazolina para el trtamiento del crecimiento celular anormal | |
| PE20221910A1 (es) | Derivados de pirazolilo utiles como agentes anticancerigenos | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
| ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| WO2016069578A1 (en) | Bromodomain inhibitors | |
| EA200100135A1 (ru) | Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| KR940701264A (ko) | 안과질환에 대한 마크로라이드 화합물의 용도 | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| TW202345836A (zh) | 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物 | |
| AR067454A1 (es) | Derivados de indano- amina, su preparacion y uso como medicamentos | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| AR045810A1 (es) | 6-[fenil (sustituidas) ] triazolopirimidinas como agentes anticancerosos | |
| AR057576A1 (es) | Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| AR064680A1 (es) | Derivados de etilamino- fenilo heterociclico sustituidos, su preparacion y su uso como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |